A Phase II Study of Clinical Efficacy of Venetoclax in Combination with Azacitidine in Patients with Therapy Related Myelodysplastic Syndrome (t-MDS)

被引：1
|
作者：
Borate, Uma M. [1 ]
Dvorak-Kornaus, Kaitlyn M. [2 ]
Zhao, Qiuhong [2 ]
Koenig, Kristin L. [3 ]
Eisfeld, Ann-Kathrin [4 ]
Madanat, Yazan F. [5 ]
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, Div Hematol, Dept Internal Med, Columbus, OH USA
[2] Ohio State Univ, Div Hematol, Columbus, OH USA
[3] Ohio State Univ, Wexner Med Ctr, Dept Internal Med, Div Hematol, Columbus, OH USA
[4] Ohio State Univ, Clara D Bloomfield Ctr, Leukemia Outcomes Res, Columbus, OH USA
[5] Univ Texas Southwestern Med Ctr, Hematol Malignancies & Cellular Therapy, Dallas, TX USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-190082
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Therapy of Myelodysplastic Syndrome (MDS) with azacitidine given in combination with etanercept: A phase II study
    Holsinger, Aaron L.
    Ramakrishnan, Aravind
    Storer, Barry
    Becker, Pamela S.
    Petersdorf, Stephen
    Deeig, H. Joachim
    Scott, Bart L.
    BLOOD, 2007, 110 (11) : 435A - 435A
  • [2] A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
    Desikan, Sai Prasad Prasad
    Montalban-Bravo, Guillermo
    Ohanian, Maro
    Daver, Naval
    Yilmaz, Musa
    Konopleva, Marina
    Kadia, Tapan M.
    Venugopal, Sangeetha
    Schneider, Heather
    Chien, Kelly S.
    Kanagal-Shamanna, Rashmi
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2021, 138 : 3704 - +
  • [3] Clinical Features and Outcomes of 666 Cases with Therapy-Related Myelodysplastic Syndrome (t-MDS)
    Abd El-Fattah, Mohamed
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2018, 34 (01) : 83 - 90
  • [4] Clinical Features and Outcomes of 666 Cases with Therapy-Related Myelodysplastic Syndrome (t-MDS)
    Mohamed Abd El-Fattah
    Indian Journal of Hematology and Blood Transfusion, 2018, 34 : 83 - 90
  • [5] A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
    Navada, Shyamala C.
    Silverman, Lewis R.
    Hearn, Katherine P.
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney
    Konopleva, Marina
    Borthakur, Gautam
    Pemmaraju, Naveen
    Kadia, Tapan
    Fenaux, Pierre
    Fruchtman, Steve
    Azarnia, Nozar
    Garcia-Manero, Guillermo
    BLOOD, 2015, 126 (23)
  • [6] A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)
    Garcia-Manero, Guillermo
    Sasaki, Koji
    Montalban-Bravo, Guillermo
    Daver, Naval G.
    Jabbour, Elias J.
    Alvarado, Yesid
    DiNardo, Courtney D.
    Ravandi, Farhad
    Borthakur, Gautam
    Bose, Prithviraj
    Pemmaraju, Naveen
    Naqvi, Kiran
    Cortes, Jorge E.
    Kadia, Tapan M.
    Konopleva, Marina Y.
    Colla, Simona
    Yang, Hui
    Rausch, Caitlin R.
    Gasior, Yvonne
    Bueso-Ramos, Carlos E.
    Kanagal-Shamanna, Rashmi
    Patel, Keyur P.
    Kantarjian, Hagop M.
    BLOOD, 2018, 132
  • [7] Azacitidine in Combination With Venetoclax for Myelodysplastic Syndrome (MDS) With Increased Blasts-2 in Clinical Practice Setting
    Davainiene, Birute
    Cepulyte, Ruta
    Trociukas, Igoris
    Pileckyte, Regina
    Griskevicius, Laimonas
    Zucenka, Andrius
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S287 - S287
  • [8] A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Daver, Naval
    Jabbour, Elias
    Jain, Nitin
    Cortes, Jorge E.
    Estrov, Zeev
    Borthakur, Gautam
    Dong, Xiao Q.
    Kumar, Veeral J.
    Kantarjian, Hagop M.
    BLOOD, 2013, 122 (21)
  • [9] CLINICAL AND PROGNOSTIC CHARACTERISTICS OF 484 PATIENTS WITH THERAPY-RELATED MYELODYSPLASTIC SYNDROME (T-MDS) OR ACUTE MYELOID LEUKEMIA (T-AML)
    Kuendgen, A. K.
    Haase, D.
    Giagounidis, A.
    Blum, S.
    Fischer, S.
    Platzbecker, U.
    Schlenk, R.
    Hildebrandt, B.
    Valent, P.
    Stadler, M.
    Stauder, R.
    Krieger, O.
    Goetze, K.
    Hofmann, W. K.
    Ganser, A.
    Mende, C.
    Haas, R.
    Gattermann, N.
    Germing, U.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 284 - 285
  • [10] A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Wilhelm, Francois
    Hearn, Katherine
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Azarnia, Nozar
    Silverman, Lewis R.
    BLOOD, 2014, 124 (21)
12345